Vorasidenib (AG-881)

Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor.

Signaling Pathways >> Metabolic Enzyme/Protease >> Isocitrate Dehydrogenase (IDH)

Research Areas >> Cancer

IDH[1]

Vorasidenib has recently entered phase 1 clinical trials in hematologic (NCT02492737) and solid malignancies (NCT02481154) in patients with either an IDH1 or an IDH2 mutation. Preclinical studies have suggested that Vorasidenib fully penetrates the blood-brain barrier and may be a more effective option for patients with IDH1/2 mutated glioma[1].

[1]. Fujii T, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016 May;21(117):373-80.

AG-120 | Enasidenib | AGI-5198 | AGI-6780 | GSK864 | IDH-305 | BAY-1436032 | Mutant IDH1 inhibitor | Mutant IDH1-IN-1 | Mutant IDH1-IN-2 | Olutasidenib